Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 1.00 |
| ▸ | CDK1 | P06493 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.73 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513970 | 0.89 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL1447655 | 0.86 | CDK2 (0.80) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL4518394 | 0.85 | CDK2 (0.74) | CDK2CDK1KCNH2 | |
| SCHEMBL1447613 | 0.83 | CDK2 (0.81) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924704 | 0.83 | KCNH2 (0.82) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447239 | 0.83 | CDK2 (0.82) | CDK2CDK1KCNH2 | |
| Lithium Ion SCHEMBL2924705 | 0.82 | KCNH2 (0.81) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL2924335 | 0.82 | CDK2 (0.81) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL4248462 | 0.81 | CDK2 (0.72) | CDK2CDK1KCNH2 | |
| SCHEMBL4516321 | 0.81 | CDK2 (1.00) | CDK2CDK1KCNH2CDK4CDKL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | CDK2 4/4885CDK1 6/4885KCNH2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.